The Marie-Josée and Henry R. Kravis Drug Discovery Institute

Medicinal Chemistry

Drug discovery target identification and validation to meet the needs of patients has become even more challenging in spite of the huge amounts of genomic and metabolomic data available today. Close collaboration between biological and chemical sciences is vital to determine biological mechanisms of disease and to discover approaches to positively impact the disease state through intervention using molecular therapeutics.

The research program of our Medicinal Chemistry laboratory develops novel chemical and biological tools in collaboration with our colleagues across the wide variety of therapeutic areas of interest to the Mount Sinai research community. Targets meeting sufficient criteria of validation have the opportunity to enter into our drug discovery portfolio.

An important focus of our laboratory is to develop key chemical and biochemical tools necessary to create translational and target engagement biomarkers, including imaging agents, to further understand the impact on disease states and underlying biology to effectively intervene in the designated disease pathway.

We work toward the identification of novel chemical matter by developing new chemical processes and syntheses in the areas of heterocyclic chemistry and carbon-carbon bond forming reactions to access unexploited chemical space.

Our expertise includes:

  • Fully equipped synthetic chemistry laboratories
  • Major instrumentation such as chromatography, HPLC, NMR, LC-MS (SCB)
  • Evaluation of high throughput and virtual screens
  • Hit validation and follow-up
  • Lead identification
  • Chemical tools for in vivo studies in preclinical animal models of disease
  • Lead optimization to identify candidates for clinical studies